| NCT ID | NCT06393894 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pauls Stradins Clinical University Hospital |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2019-04-01 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2019-04-01 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atherosclerosis and its complications are a global problem. There are several widely known and proven risk factors that promotes atherogenesis in the majority of patients. However, significant proportion of apparently healthy and young patients with cardiovascular disease but yet without recognized atherogenesis promoting risk factors can be observed in clinical practice. It highlights the need of new risk markers for early atherosclerosis diagnostics to prevent serious cardiovascular complications in these patients and in population in general. The interest in the negative impact of genetic variance, gene regulation on atherogenesis is growing. Therefore the purpose of this study is to analyze the impact of genetic variance and microRNA expression on early atherosclerosis development in the population of young, apparently healthy patients with coronary atherosclerosis. The primary hypothesis is that the group of patients with premature atherosclerosis have common genetic variations promoting early atherosclerosis development. The secondary hypothesis is that specific circulating microRNA expression (miR-126, miR-145 and miR-155) correlate with plaque lipid core by near infrared spectroscopy (NIRS) analysis.
Eligibility Criteria
Inclusion criteria: * Signed informed consent * Early atherosclerosis defined as coronary atherosclerosis in men aged \<55 years and women \<65 years * Coronary artery atherosclerosis with angiographically proven coronary vessel luminal stenosis ≥ 50% and ischaemia * Coronary artery atherosclerosis with planned revascularization * History of coronary artery revascularization (PTCA or coronary artery bypass surgery) * Coronary vessel suitable for NIRS pullback Exclusion criteria: * Diabetes * Total cholesterol ≥7 mmol/l and/or LDL ≥ 5 mmol/l * family hypercholesterolemia * positive family history of early cardiovascular disease (myocardial infarction, sudden cardiac death or cardiovascular disease of first degree relatives at young age - men \<55 years, women \<65 years) * malignant or resistant hypertension ≥ 10 years * body mass index ≥40 kg/m 2 ) * 20 or more pack years of smoking
Frequently Asked Questions
Who can join the NCT06393894 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06393894 currently recruiting?
Yes, NCT06393894 is actively recruiting participants. Visit ClinicalTrials.gov or contact Pauls Stradins Clinical University Hospital to inquire about joining.
Where is the NCT06393894 trial being conducted?
This trial is being conducted at Riga, Latvia.
Who is sponsoring the NCT06393894 clinical trial?
NCT06393894 is sponsored by Pauls Stradins Clinical University Hospital. The trial plans to enroll 100 participants.